China Medical's HER-2 FISH breast cancer test approved in China
This article was originally published in Clinica
Executive Summary
China Medical Technologies' breast cancer HER2 FISH probe has been approved by the Chinese state FDA (SFDA). It is the first fluorescence in situ hybridisation (FISH) probe to get the go-ahead in the country, the Beijing-based company claims. FISH can detect amplification of the HER2 gene status and be used to tailor treatment – Roche's HER2-targeting drug Herceptin (trastuzumab) is effective in those with HER2-positive cancer. China Medical launched a FISH test for prostate cancer in July 2008 (see Clinica No 1302, p 12).